Consistent with these findings, Nakatsu et al. reported that one week of luseogliflozin administration suppressed the hyperglycemia-induced release of tumor necrosis factor-α (TNF-α), IL-1, and IL-6 [32]. The gene discussed is TNF; the disease is Hyperglycemia.